News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Aug 6, 2019

Summary Toggle Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor

Dr. Briscoe to advise company on ongoing development of therapeutics based on the Neuropilin-2 (NRP2) co-receptor and related signaling pathways SAN DIEGO , Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of
Jul 10, 2019

Summary Toggle aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape

Conference Call Scheduled for Thursday, July 18th @ 2pm Eastern/11am Pacific SAN DIEGO , July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced
Jul 1, 2019

Summary Toggle aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members

SAN DIEGO , July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointments of Jane Gross , Ph.D. and Svetlana Lucas , Ph.D.
Jun 28, 2019

Summary Toggle aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance

SAN DIEGO , June 28, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its Board of Directors has approved a one-for-14 reverse stock split of
May 13, 2019

Summary Toggle aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host conference call and webcast today at 5:00pm EDT / 2:00 PDT SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE)
May 6, 2019

Summary Toggle aTyr Pharma to Announce First Quarter 2019 Results on May 13th

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it
Apr 16, 2019

Summary Toggle aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology

Meeting to feature presentations on recent NRP-2-related discoveries by leading research experts in the field SAN DIEGO , April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Apr 11, 2019

Summary Toggle aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund

SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated
Apr 8, 2019

Summary Toggle aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference

ATYR1923 shown to modulate inflammatory and fibrotic processes in multiple interstitial lung disease (ILD) animal models SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based
Mar 25, 2019

Summary Toggle aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO , March 25, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the